The Women on the 6th Floor

Abacus Life, Inc. Prices Public Offering of $31.0 Million 9.875% Notes Due 2028

Retrieved on: 
Friday, November 3, 2023
Sale, The Women on the 6th Floor, Security (finance), Note, Alston & Bird, Prospectus, Ladenburg Thalmann, 1251 Avenue of the Americas

ORLANDO, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) today announced that it has priced an underwritten public offering of $31.0 million in aggregate principal amount of its 9.875% notes due 2028 (the “Notes”).

Key Points: 
  • ORLANDO, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) today announced that it has priced an underwritten public offering of $31.0 million in aggregate principal amount of its 9.875% notes due 2028 (the “Notes”).
  • The Company has granted the underwriters an option to purchase up to an additional $4.65 million in aggregate principal amount of notes solely to cover overallotments, if any.
  • The offering is expected to close on November 10, 2023, subject to customary closing conditions.
  • Piper Sandler & Co., Ladenburg Thalmann & Co. Inc. and InspereX LLC are serving as joint book-running managers for the offering.

Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
Thursday, October 26, 2023
Capital market, Sale, Register, The Women on the 6th Floor, Toronto Stock Exchange, EDGAR, Registration statement, Form, News, Option, Private, Attention, Investissement Québec, Indian stock exchange, Public, Marathon Asset Management, TSX, Security (finance)

MONTREAL, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has priced its previously announced public offering (the “Public Offering”) of 12,500,000 common shares of the Company (the “Common Shares”) at a public offering price of US$1.00 per Common Share (the “Offering Price”). The gross proceeds of the Public Offering are expected to be approximately US$12,500,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriter a 30-day option (the “Option”) to purchase up to 1,875,000 Common Shares at the Offering Price, less underwriting discounts and commissions.

Key Points: 
  • MONTREAL, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has priced its previously announced public offering (the “Public Offering”) of 12,500,000 common shares of the Company (the “Common Shares”) at a public offering price of US$1.00 per Common Share (the “Offering Price”).
  • The gross proceeds of the Public Offering are expected to be approximately US$12,500,000, before deducting the underwriting discounts and commissions and other estimated offering expenses.
  • In connection with the Public Offering, the Company entered into a subscription agreement with Investissement Québec for a concurrent private placement (the “Concurrent Private Placement”) of 9,118,184 Common Shares and 3,381,816 fully-funded, non-voting subscription receipts, exchangeable into Common Shares on a one-for-one basis (the “Exchangeable Subscription Receipts”) in lieu of Common Shares, in each case, at the Offering Price, for US$12,500,000 aggregate gross proceeds, less a capital commitment fee of 1.5% payable to Investissement Québec.
  • The closing of the Public Offering and the Concurrent Private Placement are conditional upon each other.

Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
Wednesday, October 25, 2023
Capital market, Sale, Register, The Women on the 6th Floor, Toronto Stock Exchange, EDGAR, Registration statement, News, Private, Attention, Public offering, Indian stock exchange, Public, TSX, Security (finance)

MONTREAL, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a marketed public offering (the “Public Offering”) of common shares of the Company (the “Common Shares”). The Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of Common Shares to be sold pursuant to the Public Offering (the “Option”).

Key Points: 
  • MONTREAL, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the launch of a marketed public offering (the “Public Offering”) of common shares of the Company (the “Common Shares”).
  • In connection with the Public Offering, the Company intends to enter into a subscription agreement with Investissement Québec for a concurrent private placement of Common Shares (and Common Share equivalents in the form of pre-funded, non-voting subscription receipts, exchangeable into Common Shares on a one-for-one basis (the “Exchangeable Subscription Receipts”) in lieu of Common Shares), for up to US$12.5 million aggregate gross proceeds (the “Concurrent Private Placement”).
  • The consummation of the Concurrent Private Placement will be contingent upon the closing of the Public Offering.
  • Completion of the Public Offering and Concurrent Private Placement will be subject to customary closing conditions, including the listing of the Common Shares and the Common Shares underlying the Exchangeable Subscription Receipts on the Toronto Stock Exchange and the submission of notice to the Nasdaq Global Market.

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, October 10, 2023
The Women on the 6th Floor, Telephone, Attention, UBS, Prospectus, Capital market, Nicollet Mall, Exercise, SAN, CD47, Security (finance), Sale

ALX Oncology sold 8,663,793 shares of common stock, which included 1,293,103 shares of common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,250,000 shares of common stock in the offering.

Key Points: 
  • ALX Oncology sold 8,663,793 shares of common stock, which included 1,293,103 shares of common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,250,000 shares of common stock in the offering.
  • The shares of common stock were sold at a public offering price of $6.38 per share, the closing price on October 4, 2023, and the pre-funded warrants were sold at a public offering price of $6.379 per pre-funded warrant.
  • The gross proceeds to ALX Oncology from this offering were approximately $63.2 million, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants.
  • All shares of common stock and pre-funded warrants were offered by the Company.

ALX Oncology Announces Pricing of Public Offering

Retrieved on: 
Thursday, October 5, 2023
The Women on the 6th Floor, Telephone, Attention, UBS, Prospectus, Capital market, Nicollet Mall, Exercise, SAN, CD47, Security (finance), Sale

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants.
  • ALX Oncology is selling 7,370,690 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,250,000 shares of common stock in the offering.
  • The gross proceeds to ALX Oncology from this offering are expected to be approximately $55.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any pre-funded warrants.
  • In addition, ALX Oncology has granted the underwriters a 30-day option to purchase up to an additional 1,293,103 shares of its common stock at the public offering price per share less underwriting discounts and commissions.

Energy Transfer LP Announces Pricing of $4.0 Billion of Senior Notes

Retrieved on: 
Tuesday, October 10, 2023
Oil, Gas, Energy, Transfer, Partnership, Sunoco, NYSE, The Women on the 6th Floor, 1221 Avenue of the Americas, USAC, Transport, SUN, NGL, Sale, Energy Transfer Partners, Petroleum, LP

Energy Transfer LP owns and operates one of the largest and most diversified portfolios of energy assets in the United States, with nearly 125,000 miles of pipeline and associated energy infrastructure.

Key Points: 
  • Energy Transfer LP owns and operates one of the largest and most diversified portfolios of energy assets in the United States, with nearly 125,000 miles of pipeline and associated energy infrastructure.
  • Energy Transfer’s strategic network spans 41 states with assets in all of the major U.S. production basins.
  • Energy Transfer is a publicly traded limited partnership with core operations that include complementary natural gas midstream, intrastate and interstate transportation and storage assets; crude oil, natural gas liquids (“NGL”) and refined product transportation and terminalling assets; and NGL fractionation.
  • Energy Transfer also owns Lake Charles LNG Company, as well as the general partner interests, the incentive distribution rights and approximately 34% of the outstanding common units of Sunoco LP (NYSE: SUN), and the general partner interests and approximately 47% of the outstanding common units of USA Compression Partners, LP (NYSE: USAC).

ALX Oncology Announces Proposed Public Offering

Retrieved on: 
Wednesday, October 4, 2023
Attention, CD47, The Women on the 6th Floor, Capital market, Telephone, Sale, Prospectus, SAN, Security (finance), Nicollet Mall

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
  • All shares of common stock and pre-funded warrants in this offering will be sold by ALX Oncology.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • ALX Oncology intends to use the net proceeds from the offering to fund ongoing development of evorpacept, including clinical trials targeting market expansion, and for working capital and general corporate purposes.

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Retrieved on: 
Tuesday, October 3, 2023
Attention, NORTH, The Women on the 6th Floor, Capital market, ADS, ANL, Sale, Prospectus, Security (finance)

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the closing of its previously announced initial public offering of 2,500,000 American depositary shares (“ADSs”), each representing three Class A ordinary shares at a public offering price of US$23.00 per ADS.

Key Points: 
  • SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the closing of its previously announced initial public offering of 2,500,000 American depositary shares (“ADSs”), each representing three Class A ordinary shares at a public offering price of US$23.00 per ADS.
  • All of the ADSs were offered by Adlai Nortye.
  • In addition, Nippon Kayaku Co., Ltd., a chemical company headquartered in Japan, acquired a total of 5,217,391 Class A ordinary shares from Adlai Nortye in a private placement concurrent with the closing of the public offering at the same per share purchase price.
  • Adlai Nortye received aggregate gross proceeds of US$57.5 million from the public offering (before deducting underwriting discounts and commissions and offering expenses) and US$40.0 million from the concurrent private placement.

Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, October 2, 2023
Exercise, Attention, Therapy, The Women on the 6th Floor, Capital market, Oppenheimer, Telephone, Sinclair Investments (UK) Ltd v Versailles Trade Finance Ltd, Sale, Prospectus, Form S-3, Form, Madison Avenue, Security (finance), Rare, Guggenheim Partners

The gross proceeds of the public offering were $69.0 million, before deducting the underwriting discount and other estimated offering expenses.

Key Points: 
  • The gross proceeds of the public offering were $69.0 million, before deducting the underwriting discount and other estimated offering expenses.
  • Guggenheim Securities, LLC, Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc. acted as the joint book-running managers for the public offering and placement agents for the concurrent private placement.
  • Laidlaw & Company (UK) Ltd. acted as lead manager for the offering and a placement agent for the concurrent private placement.
  • The securities described above relating to the public offering were offered by Soleno pursuant to registration statements on Form S-3 (File Nos.

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, September 29, 2023
Exercise, Attention, NORTH, The Women on the 6th Floor, Capital market, ADS, ANL, Sale, Prospectus, Security (finance)

All of the ADSs were offered by Adlai Nortye.

Key Points: 
  • All of the ADSs were offered by Adlai Nortye.
  • In addition, an investor will acquire a total of 5,217,391 Class A ordinary shares from Adlai Nortye in a private placement concurrent with the closing of the public offering at the same per share purchase price.
  • Adlai Nortye expects to receive aggregate gross proceeds of US$97.5 million, including US$57.5 million from the public offering (before deducting underwriting discounts and commissions and offering expenses, and not taking into account potential exercise of the underwriters’ over-allotment option) and US$40.0 million from the concurrent private placement.
  • Assuming the over-allotment option is exercised in full, the aggregate gross proceeds to be received by Adlai Nortye may reach up to approximately US$106.1 million.